Two doses of COVID vaccine cut the risk of infection and mild illness from the rising BA.2 subvariant, although protection wanes quickly.
collected in the United Kingdom reveal a similar trend: vaccine effectiveness against symptomatic COVID-19 is less than 20% for both subvariants 25 weeks or more after a second dose, but rises to roughly 70% 2–4 weeks after a third dose.severe disease
This analysis showed that protection against severe disease remained at 68% or higher for at least 7 months, even in people who had only received two vaccine doses, and shot up to over 80% after a booster dose. Abu-Raddad says that because 70-80% of the pooled cases were BA.2, he suspects that vaccines still offer a high level of protection against severe disease in the face of surging BA.2 levels.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna, Pfizer push for 4th doses despite only minor benefits in studyA study found Israeli healthcare workers given fourth coronavirus vaccine shot at the height of Omicron were only marginally more protected against reinfection.
Read more »
Second COVID booster shot does little to stop Omicron, study findsA study of healthcare workers finds that a second booster dose of Pfizer's COVID-19 vaccine did little to prevent Omicron infections.
Read more »
Omicron BA.2 subvariant becoming dominant, representing potential riskICYMI: Omicron BA.2 subvariant becoming dominant, representing potential risk
Read more »
NPR Cookie Consent and Choices
Read more »
Omicron BA.2 subvariant becoming dominant, representing potential risk“We are moving from a BA.1 wave to a BA.2 wave.\u0022
Read more »